Qingguo Li

Dr. Qingguo Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in ACS Nano
Verified
Journal Article
Closed access
LZLiuting Zhong
Liuting Zhong
Junqiu ZhaiJunqiu Zhai
Junqiu Zhai
YMYan Ma
Yan Ma
YHYihong Huang
Yihong Huang
YPYongrui Peng
Yongrui Peng
SGShixia Guan
Shixia Guan

1 February 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
QRQiuhong Rao
Qiuhong Rao
ZQZhenwen Qiu
Zhenwen Qiu
DHDeen Huang
Deen Huang
TLTiejun Lu
Tiejun Lu
ZZZhenyu Jason Zhang
Zhenyu Jason Zhang
QLQingguo Li
Qingguo Li

1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DHDeen Huang
Deen Huang
ZXZiyuan Xie
Ziyuan Xie
QRQiuhong Rao
Qiuhong Rao
ELEvangelos Liamas
Evangelos Liamas
PPPiaopiao Pan
Piaopiao Pan
QLQingguo Li
Qingguo Li

16 November 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
XLXuchun Li
Xuchun Li
QWQing Wang
Qing Wang
JHJiewen Huang
Jiewen Huang
XYXiao Yue
Xiao Yue
XZXuejuan Zhang
Xuejuan Zhang
ZZZiyu Zhao
Ziyu Zhao
Invasive pulmonary aspergillosis poses a significant threat to immunocompromised patients, characterized by high mortality rates. Posaconazole (PSZ), a second-generation triazole antifungal, exhibits broad-spectrum activity but suffers from limited pulmonary concentrations and notable systemic side effects when administered orally or intravenously. This study focuses on optimizing PSZ nanocrystals-agglomerated particles for dry powder inhalers (DPIs) to enhance solubility, dissolution rates, and pulmonary deposition, ultimately improving therapeutic efficacy while minimizing systemic adverse effects. We employed wet medium milling and spray-drying techniques to formulate PSZ nanocrystals-agglomerated DPIs. Various stabilizers including HPMC, HPC, Soluplus, and PVPK30, were systematically evaluated to optimize physicochemical properties. Aerosolization performance was assessed using the Next Generation Impactor, while antifungal efficacy was evaluated through in vitro and in vivo studies. The optimized PSZ DPIs demonstrated significant enhancements in solubility and dissolution rates, with a fine particle fraction (FPF) of 78.58 ± 3.21%, ensuring optimal lung delivery. In vitro experiments revealed potent effects with minimal cytotoxicity to lung cells. In vivo studies indicated that the optimized formulation achieved a Cmax/AUC0→∞ ratio in lung tissues that was 27.32 and 6.76-fold higher than that of the oral suspension, highlighting increased local drug concentrations. This approach presents a scalable, cost-effective strategy for the pulmonary delivery of PSZ, ensuring high drug loading and promising clinical outcomes in treating pulmonary fungal infections.

7 November 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ZMZhimin Ma
Zhimin Ma
XZXuejuan Zhang
Xuejuan Zhang
LPLu Ping
Lu Ping
ZZZicheng Zhong
Zicheng Zhong
XZXiubing Zhang
Xiubing Zhang
DLDandong Luo
Dandong Luo

1 March 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
XZXiaoting Zhang
Xiaoting Zhang
QRQiuhong Rao
Qiuhong Rao
ZQZhenwen Qiu
Zhenwen Qiu
YLYisheng Lin
Yisheng Lin
LZLei Zhang
Lei Zhang
QLQingguo Li
Qingguo Li